Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients

Anticancer Research

Volumn 19, Issue 4 B, 1999, Pages 2907-2916

  Kim, Dong Kyu ^a,b   Lee, Tom V ^a   Castilleja, Agapito ^a   Anderson, Brett W ^a   Peoples, George E ^a   Kudelka, Andrzej P ^a   Murray, James L ^a   Sittisomwong, Tul ^a   Wharton, J Taylor ^a   Kim, Jae Wook ^b   Ioannides, Constantin G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Breast cancer; CTL; Cytotoxic T lymphocytes; FBP; Folate binding protein; Ovarian cancer; T cell receptor; TAL; TCR; Tumor associated lymphocytes

Indexed keywords

CD14 ANTIGEN; FOLATE BINDING PROTEIN; INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

BREAST NEOPLASMS; CARRIER PROTEINS; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, CELL SURFACE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033452593     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18: 175-182, 1997.
2. Ioannides CG, Fisk B, Fan D. Biddision WA, Wharton JT and O'Brian CA: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER2/neu proto-oncogene. Cell Immunol 151: 225-34, 1993.
3. Dyall R, Bowne WB, Weber LW, Lemaoult J, Szabo P, Moroi Y, Piskun G, Lewis JJ, Houghton AN and Nikolic-Zugic J: Heteroclitic immunization induces tumor immunity. J Exp Med 188: 1553-61, 1998
4. Grohmann U, Fioretti MC, Bianchi R, Belladonna ML, Ayroldi E, Surace D, Silla S and Puccetti P: Dendritic cells, interleukm 12 and CD4+ lymphocytes in the initiation of class I restricted reactivity to a tumor/self peptide. Crit Rev Immunol 18: 87-98, 1998.
5. Murphy G, Tjoa B, Ragde H, Kenny G and Boynton A: Phase I clinical trial: T cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201 specific peptides from prostate specific membrane. Prostate 29: 371-80, 1996.
6. Mortarini RA, Anichini A, DeNicola M, Siena S, Bregni M, Belli F, Molla A, Gianni AM, and Parmiani G: Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of Melan-a/Mart-127-35-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursor. Cancer Res 57: 5534-5541, 1997.
7. Van Elsas A, Van der Burg SH, Van der Minne CE, Borghi M, Mourer JS, Melief CJ and Schrier PI: Peptide pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stablly HLA-A0201 binding peptides from the melan-A/MART-1 self antigen. Eur J Immunol 26: 1683-9, 1996.
8. Carbone FR, Moore MW, Sheil JM and Bevan MJ: Induction of cytotoxic T lymphocytes by primary in vitro stimulation with peptides. J Exp Med 167: 1767-79, 1988.
9. Kelly JM, Sterry SJ, Cose S, Turner SJ, Fecondo J, Rodda S, Fink PJ and Carbone FR: Identification of conseved T cell receptor CDR3 residues contacting known exposed peptide side chains from a major higtocompatibility complex class I bound determinat. Eur J Immunol 23: 3318-26, 1993.
10. Cole DJ, Wilson MC, Rivoltini L, Custer M and Nishimura MI: T cell receptor repertoire in matched MART-1 peptide stimulated peripheral blood lymphocytes and tumor infiltrating lymphocytes. Cancer Res 57: 5320-7, 1997.
11. Clay TM, Custer MC, McKee MD, Parkhurst M, Robbins PF, Kerstann K, Wunderlih J, Rosenberg SA and Nishimura MI: Change in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with peptide modifed at an HLA-A2.1 anchor residue. J Immunol 162: 1749-1755, 1999.
12. Zaks TZ and Rosenherg SA: Immunization with peptide epitope (p.369-377) from HER-2/neu lead to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu + tumor. Cancer Res 58: 4902-8, 1998.
13. Fisk B, Chesak B, Pollack M, Wharton JT and Ioannides CG: Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Cell Immunol 157: 412-27, 1994.
14. Disis ML, Smith JW, Murphy AE, Chen W and Cheever MA: In vitro generation of human cytolytic T cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res 54: 1071-6, 1994.
15. Brossart P, Stuhler G, Flad T, Stevanovic S, Rammensee HG, Kanz L and Brugger W: HER-2/neu-derived peptides are tumor associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res 58: 732-6, 1998.
16. Perez-Diez A, Butterfield L.H, Li L, Chakraborty NG, Economou JS and Mukherji B: Generation of CD8 + and CD4 + T cell response to dendritic cells genetilcally engineered to express the MART-1/Melana gene. Cancer Res 58: 5305-9, 1998.
17. Troy AJ, Summers KL, Davidson PJ, Atkinson CH and Hart DN: Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 4: 585-93, 1998.
18. Caux P, Favre N, Bonnotte B, Moutet M, Martin M and Martin F: Tumor infiltrating dendritic cells are detective in their antigen presentating function and inducible B7 expression. A role in the immune tolerance to antignic tumors. Adv Exp Med Biol 417: 525-8, 1997.
19. PickL WF, Majdic O, Kohl P, Stockl J, Tiedl E, Scheinecker C, Bello-Fernandes C and Knapp W: Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. J Immunol 157: 3850-3859, 1996.
20. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL and Freedman RS: Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 51: 4257-65, 1991.
21. Peoples GE, Anderson BW, Fisk B, Kudelka AP, Wharton JT and Ioannides CG: Ovarian cancer associated lymphocyte recognition of folate binding protein peptides. Ann Surg Oncol. 5: 743-750, 1998.
22. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL, Old LJ and Rettig WJ: Trophoblastic and ovarian cancer antigen LK-2: Sensitivity and specificity in immunopathology and molecular identification as folate binding protein. Am J Pathol 142: 557-67, 1993.
23. Alberti S, Miotti S, Fornano M. et al. The CA-Mov18 molecule, a cell suface marker of human ovarian carcinomas, is anchored to the cell membrane by phosphatidylinositol. Biochem Biophys Res Commun 171: 1051-5, 1990.
24. Elwood PC: Molecular cloning and characterization of the human folate binding protein cDNA from placenta and malignant tissue culture KB cell. J Biol Chem 264: 14893-901, 1989.
25. Li PY, Del Vecchio S, Fonti R, Carriero MV, Potena MI, Botti G, Motti S, Lastoria S, Menard S, Colnaghi MI and Salvatore M: Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography. J Nucl Med 37: 665-72, 1996.
26. Fisk B, Blevins TL, Wharton JT and Ioannides CG: Identification of an immunodominant peptide of the HER2/neu proto-oncogene recognized by ovarian tumor specific CTL lines. J Exp Med 181: 2709-17, 1995.
27. Anderson BW, Swearingen BJ, Wharton JT and Ioannides CG: Primary generation of human antitumor CTL by a HLA-A2 restricted HER-2 peptide. Proc of AACR 38: A1606, 1997.
28. Fisk B, Flytzanes CN, Pollack MS, Wharton JT and Ioannides CG: Characterization of T-Cell Receptor V Repertoire in Ovarian Tumor Reacting CD3+CD8+ CD4-CTL Lines. Scand J Immunol 40: 591-600, 1994.
29. Peoples GE, Coedegebuure PS, Smith R, Linehan DC, Yoshino I and Eberlein TJ: Breast and ovarian cancer specific cytotoxic T lymphocytes recognize the same HER2/neu derived peptide. Proc Natl Acad Sci USA 92: 432-436, 1995.
30. Weidmann E, Giorda R, Whiteside TL, Herberman RB and Trucco M: The T cell receptor V beta gene usage in tumor infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Cancer Res 52: 5913-20, 1991.
31. Ferrandini L, Roman-Roman S and Axocar J: Analysis of T cell receptor alpha-beta variability in lymphocytes infiltrating a melanoma metastasis. Cancer Res 52: 4649-54, 1992.
32. Peoples GE, Yoshiro I, Couville CC, Andrew JVR, Goedegeburre PS and Eberlein TJ: TCR V(3+ and V(6+ CTL recognize tumor associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancer. J Immunol 152: 4993-4999, 1994.
33. Peoples GE, Goedegebuure PS, Andrews JVR, Schoof DD and Eberlein TJ: HLA-A2 presents shared tumor associated antigens derived from endogenous proteins in ovarian cancer. J. Immunol 151: 5481-91, 1993.
34. Sensi M and Parmiani G: Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Immunol Today 16: 588-604, 1995.
35. Rosenberg SA, Yannelli JR, Yanng C, Topalian SL, Schwartneztruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH and White DE: Treatment of patients with metastatic melanoma with autologous tumor infiltrating lymphocytes and Interleukin-2. J Natl Cancer Inst 86: 1159-66, 1994.
36. Repmann R, Wagner S and Richter A: Ajuvant therapy of renal cell carcinoma with active specific immunotherapy using autologous tumor vaccine. Anticancer Res 17: 2879-82, 1997.
37. Fujita K, Ikarashi H, Tanaka K, Kodama S, Tokunaga A, Takahashi T and Tanaka K: Prolonged disease free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor infiltrating lymphocytes. Clin Cancer Res 1: 501-7, 1995.